Table 1 The distribution of FANCA promoter polymorphism genotypes in breast and ovarian cancer cases and controls
Study Group | No. | 11 | 12 | 22 | 12 + 22 | ||
|---|---|---|---|---|---|---|---|
| Â | Â | n (%) | n (%) | n (%) | n (%) | p valuea | ORb (95% CI) |
Control | 256 | 112 (43.8) | 115 (44.9) | 29 (11.3) | 144 (56.2) | Â | Â |
All Breast Cancer | 352 | 164 (46.6) | 150 (42.6) | 38 (10.8) | 188 (53.4) | 0.51 | 0.89 (0.64–1.23) |
   Diagnosis ≤ 40 years | 203 | 104 (51.2) | 79 (38.9) | 20 (9.9) | 99 (48.8) | 0.13 | 0.74 (0.51–1.07 |
   Family History | 105 | 39 (37.1) | 53 (50.5) | 13 (12.4) | 66 (62.9) | 0.29 | 1.32 (0.83–2.10) |
   Bilateral Disease | 44 | 21 (47.7) | 18 (40.9) | 5 (11.4) | 23 (52.3) | 0.63 | 0.85 (0.45–1.62) |
All Ovarian Tumours | 390 | 202 (51.8) | 153 (39.2) | 35 (9.0) | 188 (48.2) | 0.05 | 0.72 (0.53–0.99) |
   All Malignant | 313 | 157 (50.2) | 126 (40.2) | 30 (9.6) | 156 (49.8) | 0.13 | 0.77 (0.55–1.08) |
Serous | 127 | 62 (48.8) | 52 (40.9) | 13 (10.2) | 65 (51.1) | 0.38 | 0.81 (0.53–1.25) |
Endometrioid | 82 | 44 (53.6) | 29 (35.4) | 9 (11.0) | 38 (46.4) | 0.13 | 0.67 (0.41–1.11) |
Mucinous | 42 | 23 (54.8) | 16 (38.1) | 3 (7.1) | 19 (45.2) | 0.24 | 0.64 (0.33–1.24) |
Clear Cell | 13 | 4 (30.8) | 8 (61.5) | 1 (7.7) | 9 (69.2) | 0.40 | 1.75 (0.52–5.83) |
Adenocarcinoma | 49 | 24 (49.0) | 21 (42.8) | 4 (8.2) | 25 (51.0) | 0.53 | 0.81 (0.44–1.49) |
   Borderline | 15 | 6 (40.0) | 8 (53.3) | 1 (6.7) | 9 (60.0) | 1.00 | 1.16 (0.40–3.37) |
   Benign | 62 | 39 (62.9) | 19 (30.6) | 4 (6.4) | 23 (37.0) | 0.007 | 0.46 (0.26–0.81) |